Stopping
cancer in its tracks
(continued)
"Blood
vessels are the body's pipeline for nutrients - they are like pipelines
bringing energy or water into a city. In cases of prostate cancer,
urokinase burrows the pipeline into the tumor."
Evans
also believes urokinase plays a role in prostate cancer that doesn't
respond to the suppression of testosterone, also known as hormone-refractory
prostate cancer.
Testosterone
is like fertilizer for prostate cancer, much the way that estrogen
helps breast cancer to grow. "Prostate cancer is androgen-regulated.
Fifty years ago a scientist won the Nobel Prize for observing that
removing testosterone improved survival for metastatic prostate
cancer. Even today, most treatments involve injections of drugs
that keep men with prostate cancer from producing the male sex hormone,"
says Evans.
"But
in all cases, prostate cancer eventually continues to grow in the
absence of testosterone. We don't have a lot of options for men
once this happens."
A
urologic oncology surgeon who splits his time between the operating
room and the lab, Evans has been studying angiogenesis for more
than 10 years. He started with a two-year stint at the Walter Reed
Army Institute of Research collaborating with the Section of Tumor
Invasion and Metastasis at the National Cancer Institute. Next he
went to UC San Francisco for surgical and urology training and a
one-year research fellowship from the National Kidney Foundation.
This was followed by a two-year fellowship in urologic oncology
at M.D. Anderson Cancer Center in Houston.
Home |
Table of Contents |
To our Readers |
Building on Basics
Focusing on Patients |
In Translation |
First Steps
Campus Connection |
Benefactors |
News in Brief
UC Davis Health System |
© 2000, 2001, 2002 UC Regents. All rights reserved.
|